Idiopathic Pulmonary Fibrosis in the Era of Antifibrotic Therapy: Searching for New Opportunities Grounded in Evidence

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that up to now has been associated with a poor prognosis. However, the results of the INPULSIS and ASCEND trials and the approval of nintedanib and pirfenidone have marked the beginning of a new era for IPF patients. Questio...

ver descrição completa

Detalhes bibliográficos
Autor principal: Robalo-Cordeiro, C (author)
Outros Autores: Campos, P (author), Carvalho, L (author), Borba, A (author), Clemente, S (author), Freitas, S (author), Furtado, S (author), Jesus, JM (author), Leal, C (author), Marques, A (author), Melo, N (author), Souto-Moura, C (author), Neves, S (author), Sousa, V (author), Santos, A (author), Morais, A (author)
Formato: article
Idioma:eng
Publicado em: 2017
Assuntos:
HSM PNEU
HSM IMA
Evidence-Based Medicine
Idiopathic Pulmonary Fibrosis/drug therapy
Indoles/therapeutic use
Pyridones/therapeutic use
Texto completo:http://hdl.handle.net/10400.17/2757
País:Portugal
Oai:oai:repositorio.chlc.min-saude.pt:10400.17/2757

Texto Completo

http://hdl.handle.net/10400.17/2757

Registos relacionados